# A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom

Source: https://onco.cc/trials/nct05100862/  
OnCo record `nct05100862` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Zanubrutinib, Rituximab, Lenalidomide in follicular lymphoma, run by BeOne Medicines, active and no longer recruiting.

## Summary

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma is a phase 3 interventional study registered as NCT05100862 by BeOne Medicines, with 799 participants enrolled, started 2022-03-10 and due to reach its primary completion in 2028-07. Interventions recorded: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab. Conditions listed: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05100862
- Phase: 3
- Setting: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Sponsor: BeOne Medicines
- Enrolled: 799

## Sources

- ClinicalTrials.gov NCT05100862: https://clinicaltrials.gov/study/NCT05100862

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Rituximab](https://onco.cc/drugs/rituximab/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct05100862.json